In the field of cancer chemotherapy small molecules have dominated. Their cytotoxic properties have targeted numerous aspects of cell proliferation with much success and new small molecules continue to be developed.
One obstacle has been a barrier to rapid progress; selectivity in killing cancer cells without killing healthy cells.
An emerging technology seeking to finally solve this problem is the combination of natural selectivity using antibodies produced by the immune system and toxic drugs in so-called antibody drug conjugates (ADCs).
This report summarises the current clinical development of ADCs and projects their future commercial potential within the next ten years. It identifies the leading companies and how their proprietary technologies are intertwined in commercial collaborations. The current clinical trial pipeline of new drug candidates and the coming online of contract manufacturing organisations is reviewed.
The report will be of interest to investors seeking to identify the companies to watch as antibody drug conjugates rapidly grow in commercial significance.
The emerging market for antibody drug conjugates (ADCs) in the treatment of cancer is reviewed. The main companies involved in developing the technology are listed along with current clinical trials. The commercial potential for ADCs is projected over the next 5-10 years.
The report identifies the companies likely to emerge as industry leaders or become takeover targets for the global pharmaceutical companies.
